



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Ravuconazole

Cat. No.:	HY-14272
CAS No.:	182760-06-1
Molecular Formula:	C ₂₂ H ₁₇ F ₂ N ₅ OS
Molecular Weight:	437.47
Target:	Fungal
Pathway:	Anti-infection
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 50 mg/mL (114.29 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.2859 mL	11.4294 mL	22.8587 mL
	5 mM		0.4572 mL	2.2859 mL	4.5717 mL
	10 mM		0.2286 mL	1.1429 mL	2.2859 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (5.71 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (5.71 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.71 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Ravuconazole (BMS-207147;ER-30346) is an orally available triazole antifungal agent that potently inhibits a wide range of fungi.
IC ₅₀ & Target	Fungal ^[1]
In Vitro	Ravuconazole shows a broad spectrum of activity against a wide range of fungi covering <i>Candida</i> spp., <i>Trichosporon beigelii</i> , <i>C. neoformans</i> and <i>A. fumigatus</i> . The MIC ₉₀ ranges from 0.025 to 0.39 mg/mL. Ravuconazole shows relatively higher levels of

activity against three strains of *Candida krusei*, with MICs ranging from 0.05 to 0.39 mg/mL. Ravuconazole shows good activity against *T. mentagrophytes*, *T. rubrum*, *M. gypseum* and *M. canis* with MICs ranging from 0.05 to 0.39 mg/mL^[1]. Ravuconazole is about two- to four fold more potent than itraconazole and about 40-fold more active than fluconazole against yeasts. Ravuconazole and itraconazole are inhibitory to most aspergilli, and against half of the isolates, the activity is cidal. Ravuconazole and itraconazole are active, though not cidal, against most hyaline *Hyphomycetes*, dermatophytes, and the dematiaceous fungi and inactive against *Sporothrix schenckii* and *zygomycetes*^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The maximum concentration of ravuconazole in plasma and the area under the concentration-time curve for ravuconazole show good linearity over a range of doses from 2 to 40 mg/kg of body weight. Ravuconazole at a dose of 2.5 mg/kg delays mortality significantly compared with the control treatment. Ravuconazole also shows a substantial therapeutic effect against systemic cryptococcosis^[1]. Ravuconazole reduces the numbers of CFU in the lungs significantly compared with the numbers of CFU in the lungs of the controls. In an experimental model of oral candidiasis in rats, ravuconazole reduces the numbers of CFU in oral swabs significantly compared with the numbers of CFU in oral swabs from the controls and is more effective than itraconazole and as effective as fluconazole.^[3] MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal

Administration^{[1][3]}

Mouse^[1]

Ravuconazole is prepared in 10% DMSO in 0.5% CMC. *C. neoformans* No. 3 is grown on an SDA plate at 30°C for 48 h, and challenge organisms are prepared in sterile saline. Mice (age, 5 weeks; n 5 10) are infected via the tail vein. Ravuconazole is orally administered, in a volume of 0.2 mL per dose, twice daily for 5 consecutive days starting 1 h after infection. Controls receive 10% DMSO in 0.5% CMC. Ravuconazole is administered at doses of 8 and 32 mg/kg. Mortality is recorded daily for 21 days of infection. Drug efficacy is assessed by determining the delay in mortality.

Rats^[3]

The rats are orally infected three times at 48-h intervals with 0.1 mL of a saline suspension containing cells of *C. albicans* E81022. Ravuconazole is orally administered, in a volume of 0.5 mL per dose, once daily for 3 consecutive days starting 2 days after the last infection. Control groups receive 10% DMSO in 0.5% CMC. Drugs are administered at doses of 1 and 4 mg/kg. Drug efficacy is assessed 5 days after the last infection by measuring the number of *C. albicans* organisms in oral swabs.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Hata K, et al. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. *Antimicrob Agents Chemother.* 1996 Oct;40(10):2237-42.
- [2]. Fung-Tomc JC, et al. In vitro activity of a new oral triazole, BMS-207147 (ER-30346) *Antimicrob Agents Chemother.* 1998 Feb;42(2):313-8.
- [3]. Hata K, et al. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. *Antimicrob Agents Chemother.* 1996 Oct;40(10):2243-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA